SCHEMBL376645

SCHEMBL376645

CCOC(=O)C(C)(C)Oc1ccc(C(O)CCc2nc(-c3ccccc3Cl)oc2C(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 12/20 0.54
PPARG P37231 11/20 0.54
PPARD Q03181 8/20 0.54
ABCB11 O95342 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
HTR2A P28223 1/20 0.42
PMP22 Q01453 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 3/20 0.36
TP53 P04637 2/20 0.36
FBP1 P09467 2/20 0.36
THRB P10828 2/20 0.35
POLB P06746 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
PTBP1 P26599 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377166 0.90 PPARA (0.66) PPARAPPARGPPARD
SCHEMBL376600 0.87 PPARA (0.56) PPARAPPARGPPARDABCB11CYP1A2
SCHEMBL377239 0.86 PPARA (0.55) PPARAPPARGPPARDABCB11CYP1A2
SCHEMBL377010 0.83 PPARA (0.52) PPARAPPARGPPARDABCB11CYP1A2
SCHEMBL381706 0.83 PPARA (0.51) PPARAPPARGPPARDABCB11CYP1A2
SCHEMBL381707 0.83 PPARA (0.51) PPARAPPARGPPARDABCB11CYP1A2
SCHEMBL376642 0.80 PPARG (0.45) PPARAPPARGPPARDCYP1A2CYP3A4
SCHEMBL376825 0.76 PPARA (0.68) PPARAPPARGPPARD
SCHEMBL376724 0.75 PPARA (0.67) PPARAPPARGPPARD
SCHEMBL24658608 0.75 PPARG (0.53) PPARAPPARGPPARDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARA 3/4885PPARG 2/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.